Targeting

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

July 27, 2020July 27, 2020Tuba Khan

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, [Read More...]

AbbVie Signs an Exclusive Research and Option to License Agreement with Sosei Heptares Targeting Inflammatory and Autoimmune Diseases

June 26, 2020June 26, 2020Tuba Khan

Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of [Read More...]

Merck Collaborates with Yumanity to Accelerate the Development of Two Therapies Targeting Neurodegenerative Diseases

June 25, 2020June 25, 2020Tuba Khan

Shots: Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive [Read More...]

Sorrento Initiates the Next Phase of its Collaboration with Celularity

Sorrento Collaborates with Mount Sinai Health System to Develop COVI-SHIELD Antibody Cocktail Targeting COVID-19

May 11, 2020May 22, 2020Shiwani Sharma

Shots: Sorrento to get access to plasma containing anti-COVID-19 Abs for identifying and produce mAbs with neutralizing activity against SARS-CoV-2. The company expects [Read More...]

Bergenbio’s Bemcentinib Selected to be Fast-Tracked Under UK’s ACCORD Program Targeting COVID-19

April 30, 2020April 30, 2020Tuba Khan

Shots: Bemcentinib has been selected as the first potential treatment to be fast-tracked under UK’s P-II ACCORD program that rapidly evaluates bemcentinib’s effectiveness [Read More...]

Celltrion Anticipates the Initiation of its First-in-Human Clinical Studies Targeting COVID-19 in July

April 14, 2020April 14, 2020Tuba Khan

Shots: Celltrion has completed the selection of therapeutic Abs which showed potency for neutralizing the SARS-CoV-2 virus and anticipates cell-line development to initiate [Read More...]

Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowel Disease

April 6, 2020April 6, 2020Tuba Khan

Shots: Second Genome will receive $38M as upfront, up to $300M milestones for each of five target discovery programs and royalties for approved [Read More...]